var data={"title":"Sotalol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sotalol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6979?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sotalol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sotalol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sotalol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sotalol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709415\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life threatening proarrhythmia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of induced arrhythmia, patients initiated or reinitiated on sotalol or sotalol AF and patients who are converted from IV to oral administration should be placed for a minimum of 3 days (on their maintenance dose) in a facility that can provide cardiac resuscitation and continuous electrocardiographic (ECG) monitoring. Do not initiate if baseline QTc interval is longer than 450 msec (Betapace/Betapace AF [when used for atrial fibrillation/atrial flutter], Sotylize, or sotalol injection). If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, prolong the duration of the infusion (injection) or discontinue the drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Calculate creatinine clearance (CrCl) prior to dosing; adjust dose based on CrCl. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Product interchange:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not substitute Sorine for sotalol AF because of significant differences in labeling (ie, patient package insert, dosing administration, safety information).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222498\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Betapace;</li>\n      <li>Betapace AF;</li>\n      <li>Sorine;</li>\n      <li>Sotylize</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222499\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sotalol;</li>\n      <li>CO Sotalol;</li>\n      <li>Dom-Sotalol;</li>\n      <li>Med-Sotalol;</li>\n      <li>Mylan-Sotalol;</li>\n      <li>Novo-Sotalol;</li>\n      <li>Nu-Sotalol;</li>\n      <li>PHL-Sotalol;</li>\n      <li>PMS-Sotalol;</li>\n      <li>PRO-Sotalol;</li>\n      <li>ratio-Sotalol;</li>\n      <li>Rhoxal-sotalol;</li>\n      <li>Riva-Sotalol;</li>\n      <li>Rylosol;</li>\n      <li>Sandoz-Sotalol;</li>\n      <li>ZYM-Sotalol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222538\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class II;</li>\n      <li>\n        Antiarrhythmic Agent, Class III;</li>\n      <li>\n        Beta-Blocker, Nonselective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222502\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Baseline QTc interval and creatinine clearance must be determined prior to initiation. If CrCl &le;60 mL/minute, dosing interval adjustment is necessary.</b> Sotalol should be initiated and doses increased in a hospital for at least 3 days with facilities for cardiac rhythm monitoring and assessment. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation/flutter (symptomatic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Substitution for oral sotalol: <b>Note:</b> The effects of the initial IV dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QTc interval, or adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> 75 mg infused over 5 hours twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose adjustment:</i> If the initial dose does not reduce the frequency of relapse and excessive QTc prolongation does not occur, may increase to 112.5 mg twice daily. If at steady state this dose still does not control arrhythmia and QTc prolongation does not occur, may further increase dose to 150 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose range:</i> Usual therapeutic dose: 112.5 mg twice daily; maximum dose: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion from oral sotalol to IV sotalol: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">80 mg oral equivalent to 75 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">120 mg oral equivalent to 112.5 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">160 mg oral equivalent to 150 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Betapace/Betapace AF, Sotylize: <i>Initial:</i> 80 mg twice daily. If the initial dose does not reduce frequency of relapse and excessive QTc prolongation does not occur after 3 days, the dose may be increased to 120 mg twice daily; may further increase to a maximum dose of 160 mg twice daily if response is inadequate and QTc prolongation is not excessive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ventricular arrhythmias (Betapace/Betapace AF, Sorine, Sotylize):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Substitution for oral sotalol: <b>Note:</b> The effects of the initial IV dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QTc interval, or adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> 75 mg infused over 5 hours twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose adjustment:</i> If the initial dose does not reduce the frequency of relapse and excessive QTc prolongation does not occur, may increase after at least 3 days to 112.5 mg twice daily. May further increase dose every 3 days in increments of 75 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose range:</i> Usual therapeutic dose: 75 to 150 mg twice daily; maximum dose: 300 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion from oral sotalol to IV sotalol: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">80 mg oral equivalent to 75 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">120 mg oral equivalent to 112.5 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">160 mg oral equivalent to 150 mg IV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> 80 mg twice daily; dose may be increased (in increments of 80 mg/day [Betapace/Betapace AF, Sotylize]) gradually to 160 to 320 mg daily; allow 3 days between dosing increments in order to attain steady-state plasma concentrations and to allow for monitoring of QT intervals</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Usual range:</i> Most patients respond to a total daily dose of 160 to 320 mg in 2 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Some patients, with life-threatening refractory ventricular arrhythmias, may require total daily doses as high as 480 to 640 mg; however, these doses should only be prescribed when the potential benefit outweighs the increased risk of adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Monomorphic VT (hemodynamically stable) (off-label use):</b> IV: 1.5 mg/kg over 5 minutes (AHA [Neumar 2010]); <b>Note:</b> Clinical trial employed standard dose of 100 mg (Ho 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Supraventricular tachycardia (off-label use): </b>Oral: Initial: 40 to 80 mg every 12 hours; maximum maintenance dose: 160 mg every 12 hours (ACC/AHA/HRS [Page 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222521\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sotalol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sotalol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Baseline QTc interval and creatinine clearance must be determined prior to initiation. If CrCl &le;60 mL/minute, dosing interval adjustment is necessary.</b> Sotalol should be initiated and doses increased in a hospital for at least 3 days with facilities for cardiac rhythm monitoring and assessment. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment. <b>Note:</b> Dosing per manufacturer, based on pediatric pharmacokinetic data; wait at least 36 hours between dosage adjustments to allow monitoring of QTc intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Atrial fibrillation/flutter (symptomatic):</b> Oral: Betapace/Betapace AF, Sotylize:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants and Children &le;2 years:</i> Dosage should be adjusted (decreased) by plotting of the child's age on a logarithmic scale; see graph or refer to manufacturer's package labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &gt;2 years and Adolescents:</i> Initial: 30 mg/m<sup>2</sup>/dose every 8 hours; may increase gradually to a maximum of 60 mg/m<sup>2</sup> every 8 hours, not to exceed adult dose (maximum adult dose: 320 mg<b>/</b>day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ventricular arrhythmias:</b> Oral: Betapace/Betapace AF, Sorine, Sotylize:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants and Children &le;2 years:</i> Dosage should be adjusted (decreased) by plotting of the child's age on a logarithmic scale; see graph or refer to manufacturer's package labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &gt;2 years and Adolescents:</i> Initial: 30 mg/m<sup>2</sup>/dose every 8 hours; may increase gradually to a maximum of 60 mg/m<sup>2</sup> every 8 hours, not to exceed adult dose (maximum adult dose: 320 mg/day)</p>\n    (<a href=\"image.htm?imageKey=DRUG%2F78350\" class=\"graphic graphic_figure\">See Age nomogram</a>)</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222503\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222504\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Dose escalations in renal impairment should be done after administration of at least 5 to 6 doses at appropriate intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: Administer every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 60 mL/minute: Administer every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;40 mL/minute: Use is contraindicated. <b>Note:</b> The manufacturer's labeling for some products (Betapace/Betapace AF, Sorine) recommend alternate dosing for patients with CrCl &lt;40 mL/minute (refer to manufacturer's labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Use is contraindicated in patients with CrCl &lt;40 mL/minute. <b>Note:</b> The manufacturer's labeling for some products (Betapace/Betapace AF, Sorine) recommend extreme caution be employed if sotalol is used in patients with renal failure undergoing hemodialysis. Multiple cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with hemodialysis (Huynh-Do 1996). Hemodialysis would be expected to reduce sotalol plasma concentrations because sotalol is not bound to plasma proteins and does not undergo extensive metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Use is contraindicated in patients with CrCl &lt;40 mL/minute. Cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with peritoneal dialysis (Dancey 1997; Tang 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; dosing in children with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QTc interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560158\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage adjustment unlikely because sotalol is not metabolized by the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9830566\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc &ge;500 msec during initiation period:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betapace/Betapace AF, Sotylize: Reduce dose, prolong the dosing interval (Sotylize), or discontinue sotalol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sotalol injection: Reduce dose, prolong the infusion time by decreasing the infusion rate, or discontinue sotalol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc &ge;520 msec (or JT interval &ge;430 msec if the QRS &gt;100 msec) during maintenance therapy (Betapace/Betapace AF, sotalol injection): Reduce dose and carefully monitor QTc until &lt;520 msec. If QTc interval &ge;520 msec on the lowest maintenance dose, discontinue sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc &ge;550 msec (Betapace/Betapace AF, Sorine): Reduce dose or discontinue sotalol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222468\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sotylize: 5 mg/mL (250 mL, 480 mL) [contains sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace: 80 mg, 120 mg, 160 mg [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace AF: 80 mg, 120 mg, 160 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sorine: 80 mg, 120 mg, 160 mg, 240 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg, 120 mg, 160 mg, 240 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222453\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222472\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Substitution for oral: Administer over 5 hours; may prolong duration of infusion if QT interval prolongs to &ge;500 msec.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodynamically stable monomorphic VT: Administer IV push over 5 minutes; use with caution because of increased risk of adverse events (eg, bradycardia, hypotension, torsade de pointes) (ACLS 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222471\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betapace/Betapace AF, Sorine, Sotylize: Treatment of documented ventricular arrhythmias (ie, sustained ventricular tachycardia), that in the judgment of the health care provider are life-threatening</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Betapace/Betapace AF, Sotylize: Maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with symptomatic atrial fibrillation/atrial flutter who are currently in sinus rhythm. Manufacturer of Sorine states substitutions should not be made for sotalol AF due to significant differences in labeling (ie, patient package insert and safety information)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">According to the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS), sotalol is not effective for conversion of atrial fibrillation to sinus rhythm but may be used to prevent atrial fibrillation (AHA/ACC/HRS [January 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Injection: Substitution for oral sotalol in those who are unable to take sotalol orally </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744909\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Atrial fibrillation in patients with hypertrophic cardiomyopathy (HCM) (alternative antiarrhythmic); Monomorphic ventricular tachycardia (hemodynamically stable); Supraventricular tachycardia; Fetal tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222546\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sotalol may be confused with Stadol, Sudafed</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace may be confused with Betapace AF</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High-alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222460\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">There is minimal clinical experience with IV sotalol; however, since exposure is similar between IV and oral sotalol, adverse reactions are expected to be similar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (dose related; 8% to 16%), chest pain (3% to 16%), palpitations (3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (dose related; 5% to 20%), dizziness (3% to 20%), headache (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (4% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (dose related; 5% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (2% to 8%), ECG abnormality (2% to 7%), hypotension (3% to 6%), cardiac failure (1% to 5%; incidence may be higher in patients with risk factors), syncope (1% to 5%), proarrhythmia (&lt;1% to 5%), torsades de pointes (dose related; 1% to 4%), peripheral vascular disorder (1% to 3%), angina pectoris (2%), presyncope (1% to 2%), cardiovascular signs and symptoms (&lt;1% to 2%), worsened ventricular tachycardia (1%), cerebrovascular accident (&le;1%), hypertension (&le;1%), vasodilation (&le;1%), prolonged Q-T interval on ECG (dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Sleep disorder (1% to 8%), insomnia (3% to 4%), anxiety (2% to 4%), depression (1% to 4%), paresthesia (1% to 4%), sensation of cold (2% to 3%), impaired consciousness (1% to 3%), mood changes (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (5%), skin rash (2% to 5%), diaphoresis (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight changes (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (4% to 10%), diarrhea (2% to 7%), abdominal pain (&lt;1% to 4%), dyspepsia (2% to 3%), abdominal distention (&lt;1% to 3%), decreased appetite (2%), change in appetite (1% to 2%), colonic disease (1% to 2%), flatulence (&lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Sexual disorder (&le;3%), genitourinary complaint (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (&lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (1% to 2%), influenza (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (2% to 7%), musculoskeletal pain (3% to 4%), musculoskeletal chest pain (2% to 3%), back pain (&lt;1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory complaint (1% to 8%), pulmonary disease (3% to 5%), tracheobronchitis (1% to 3%), asthma (&lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 3%), laboratory test abnormality (1% to 3%), AICD discharge (&lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Alopecia, clouding of consciousness, emotional lability, eosinophilia, hyperlipidemia, incoordination, increased liver enzymes, leukopenia, myalgia, paralysis, skin photosensitivity, pruritus, pulmonary edema, thrombocytopenia, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222476\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sotalol or any component of the formulation; bronchial asthma or related bronchospastic conditions; sinus bradycardia (&lt;50 bpm during waking hours [Betapace/Betapace AF, Sotylize, sotalol injection]); second- or third-degree AV block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; cardiogenic shock; uncontrolled heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Additional contraindications:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betapace/Betapace AF: When used for atrial fibrillation/flutter, either baseline QTc interval &gt;450 msec or CrCl &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sotylize, sotalol injection: Baseline QTc interval &gt;450 msec (or JT &gt;330 msec if QRS &gt;100 msec [sotalol injection]); CrCl &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for beta-adrenergic blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222457\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia/hypotension: May cause bradycardia (including heart block) and hypotension. Dose adjustments of agents that slow AV nodal conduction may be necessary when sotalol is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: <b>[US Boxed Warning]: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsades de pointes). Do not initiate if baseline QTc interval is &gt;450 msec (Betapace/Betapace AF, Sotylize, or sotalol injection). If QTc interval prolongs to 500 msec or exceeds 500 msec during therapy, reduce the dose, prolong the interval between doses, prolong the duration of the infusion (sotalol injection), or discontinue use (Betapace/Betapace AF, Sotylize, sotalol injection). Adjust the dosing interval based on creatinine clearance (CrCl). QTc prolongation is directly related to the concentration of sotalol; reduced CrCl, female gender, reduced heart rate, and large doses increase the risk of QTc prolongation and subsequent torsades de pointes. Patients initiated or reinitiated on sotalol or sotalol AF and patients who are converted from IV to oral administration should be placed for a minimum of 3 days (on their maintenance dose) in a facility that can provide cardiac resuscitation and continuous electrocardiographic (ECG) monitoring.</b> Some experts will initiate oral therapy on an outpatient basis if the patient is in sinus rhythm provided the QT interval and serum potassium are normal and the patient is not receiving any other QT-interval prolonging medications but require inpatient hospitalization if the patient is in atrial fibrillation (AHA/ACC/HRS [January 2014]). Calculation of CrCl must occur prior to administration of the first dose. Dosage should be adjusted gradually with 3 days between dosing increments to achieve steady-state concentrations, and to allow time to monitor QT intervals. Monitor and adjust dose to prevent QTc prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Sotalol is contraindicated in patients with bronchial asthma or related bronchospastic conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalances: Correct electrolyte imbalances before initiating (especially hypokalemia and hypomagnesemia) because these conditions increase the risk of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): New onset or worsening heart failure may occur during initiation or titration. Use with caution in patients with compensated heart failure; monitor for a worsening of the condition and discontinue if symptoms of heart failure occur. Use is contraindicated in patients with uncontrolled (or decompensated) heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use with caution within the first 2 weeks post-MI, especially in patients with markedly impaired ventricular function (experience limited).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Adjust dosing interval based on CrCl to decrease risk of proarrhythmia; QT interval prolongation is directly related to sotalol concentration.</b> CrCl must be calculated with dose initiation and dose increases. The use of sotalol is contraindicated in patients with CrCl &lt;40 mL/minute (sotalol injection, Sotylize, and Betapace/Betapace AF [when used for atrial fibrillation/atrial flutter]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: Oral: <b>[US Boxed Warning]: Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Betapace AF, Sorine, and Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace/Betapace AF and Sotylize). Sorine should not be substituted for sotalol AF.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency. When QTc prolongation occurs, consider weighing the risk of abrupt withdrawal of sotalol with the risk of QTc prolongation. Use of an alternative beta-blocker may be indicated if worsening angina or acute coronary insufficiency occurs when sotalol is withdrawn abruptly due to QTc prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300075\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222462\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9941&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Sotalol. Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222494\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Sotalol peak serum concentrations may be decreased if taken with food. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222464\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222480\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in the initial animal reproduction studies. Sotalol crosses the placenta and is found in amniotic fluid. Adverse events, such as fetal/neonatal bradycardia, hypoglycemia, and reduced birth weight have been observed following in utero exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth are generally recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Sotalol crosses the placenta in concentrations similar to the maternal serum and it is generally preferred for the treatment of fetal atrial flutter (Namouz-Haddad 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The clearance of sotalol is increased during the third trimester of pregnancy, but other pharmacokinetic parameters do not significantly differ from nonpregnant values (O&rsquo;Hare 1983). Use of sotalol may be considered for some cardiac arrhythmias when use of a beta-blocker is needed during pregnancy (ESC [Regitz-Zagrosek 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222481\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sotalol is excreted in breast milk in concentrations higher than those found in the maternal serum (O&rsquo;Hare 1980). Although adverse events in nursing infants have not been observed in case reports, close monitoring for bradycardia, hypotension, respiratory distress, and hypoglycemia is advised (Hackett 1990). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222466\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum creatinine (creatinine clearance), magnesium, potassium; heart rate, blood pressure; ECG (eg, QTc interval, PR interval). If baseline QTc &gt;450 msec (or JT interval &gt;330 msec if QRS over 100 msec [sotalol injection]), sotalol (Betapace/Betapace AF, Sotylize) is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betapace/Betapace AF, Sotylize: During initiation and titration period, monitor QTc interval 2 to 4 hours after each dose. If QTc interval is &ge;500 msec, reduce dose, prolong the dosing interval, or discontinue sotalol. If the QTc interval is &lt;500 msec after 3 days (after fifth or sixth dose if patient receiving once-daily dosing), patient may be discharged on current regimen. Monitor QTc interval periodically thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For IV use, measure QTc interval after completion of each infusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222456\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Beta-blocker which contains both beta-adrenoreceptor-blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) properties </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Class II effects: Increased sinus cycle length, slowed heart rate, decreased AV nodal conduction, and increased AV nodal refractoriness Sotalol has both beta<sub>1</sub>- and beta<sub>2</sub>-receptor blocking activity. The beta-blocking effect of sotalol is a noncardioselective (half maximal at about 80 mg/day and maximal at doses of 320 to 640 mg/day). Significant beta-blockade occurs at oral doses as low as 25 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Class III effects: Prolongation of the atrial and ventricular monophasic action potentials, and effective refractory prolongation of atrial muscle, ventricular muscle, and atrioventricular accessory pathways in both the antegrade and retrograde directions. Sotalol is a racemic mixture of <i>d-</i> and <i>l-</i>sotalol; both isomers have similar Class III antiarrhythmic effects while the <i>l-</i>isomer is responsible for virtually all of the beta-blocking activity. The Class III effects are seen only at oral doses &ge;160 mg/day. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222475\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Rapid; at 1 to 2 hours post dosing (steady-state), reductions in heart rate and cardiac index seen (Winters 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: When administered IV over 5 minutes for ongoing VT, onset of action is ~5 to 10 minutes (Ho 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (Hanyok 1993); decreased ~20% by meals compared with fasting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.2 to 2.4 L/kg (Hanyok 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 90% to 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates &le;1 month: 8.4 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children &gt;1 month to 24 months: 7.4 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt;2 years to &lt;7 years: 9.1 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 7 to 12 years: 9.2 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults with renal failure (anuric): Up to 69 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Pharmacokinetics of the IV formulation (administered over 5 hours) are similar to the oral formulations (Somberg 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Infants and Children 3 days to 12 years: Mean range: 2 to 3 hours; Adults: 2.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance (apparent) (Saul 2001b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &le;1 month: 11 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &gt;1 month to 24 months: 32 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;2 years to &lt;7 years: 63 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 7 to 12 years: 95 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222479\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sotalol HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/10 mL (10 mL): $1,695.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sotylize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (250 mL): $509.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Betapace AF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (60): $788.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (60): $965.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (60): $1,207.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Betapace Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $2,200.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $2,694.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $3,367.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sorine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (1): $2.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (1): $3.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (1): $4.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (1): $5.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sotalol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $256.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $341.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $427.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (100): $555.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038831\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alosot (UY);</li>\n      <li>Beta-Cardone (GB);</li>\n      <li>Betacor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Betades (IT);</li>\n      <li>Cardol (AU, TW);</li>\n      <li>Darob (AT, BG, HR, RO);</li>\n      <li>Gilucor (HR, HU);</li>\n      <li>Hipecor (CL);</li>\n      <li>Jutalex (DE);</li>\n      <li>Rentibloc (KR);</li>\n      <li>Solavert (AU);</li>\n      <li>Solet (LK);</li>\n      <li>Sorytmik (UA);</li>\n      <li>Sotacor (AR, AT, AU, BF, BJ, BR, CI, CN, CO, DK, ET, FI, GB, GH, GM, GN, HK, ID, IE, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, SC, SD, SE, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Sotagamma (LV);</li>\n      <li>Sotagard (IN);</li>\n      <li>Sotahexal (DE, HU, SG, VN, ZA);</li>\n      <li>Sotalex (BD, BE, CH, CZ, DE, FR, GR, HN, HU, IT, LU, PH, PL, PT, RU, SI, VN);</li>\n      <li>Sotalex Mite (EE);</li>\n      <li>Sotalol Knoll (HU);</li>\n      <li>Sotalon (KR);</li>\n      <li>Sotapor (ES);</li>\n      <li>Sotax (TR);</li>\n      <li>Sotoger (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;A Comparison of Antiarrhythmic-Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Near-Fatal Ventricular Arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators,&rdquo; <i>N Engl J Med</i>, 1997, 337(22):1576-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/9411221/pubmed\" target=\"_blank\" id=\"9411221\">9411221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span><span class=\"doi\">10.1097/01.AOG.0000437382.03963.88</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betapace/Betapace AF (sotalol) [prescribing information]. Zug, Switzerland: Covis Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dancey D, Wulffhart Z, and McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. <i>Can J Cardiol</i>. 1997;13(1):55-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/9039065/pubmed\" target=\"_blank\" id=\"9039065\">9039065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster CA and Aston SJ, &ldquo;Propranolol-Epinephrine Interaction: A Potential Disaster,&rdquo; <i>Plast Reconstr Surg</i>, 1983, 72(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/6867180 /pubmed\" target=\"_blank\" id=\"6867180 \">6867180 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackett LP, Wojnar-Horton RE, Dusci LJ, et al, &quot;Excretion of Sotalol in Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1990, 29(2):277-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/2306424/pubmed\" target=\"_blank\" id=\"2306424\">2306424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanyok JJ. Clinical pharmacokinetics of sotalol. <i>Am J Cardiol</i>. 1993;72:19A-26A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/8346722/pubmed\" target=\"_blank\" id=\"8346722\">8346722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7737227\"></a>Ho DS, Zecchin RP, Cooper MJ, Richards DA, Uther JB, Ross DL. Rapid intravenous infusion of d-l sotalol: time to onset of effects on ventricular refractoriness, and safety. <i>Eur Heart J</i>. 1995;16(1):81-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/7737227/pubmed\" target=\"_blank\" id=\"7737227\">7737227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7912296\"></a>Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. <i>Lancet</i>. 1994;344(8914):18-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/7912296/pubmed\" target=\"_blank\" id=\"7912296\">7912296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huynh-Do U, Wahl C, Sulzer M, et al. Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients. <i>Nephrol Dial Transplant</i>. 1996;11(6):1153-1154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/8671988/pubmed\" target=\"_blank\" id=\"8671988\">8671988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuhlkamp V, Mewis C, Mermi J, et al, &ldquo;Suppression of Sustained Ventricular Tachyarrhythmias: A Comparison of d,1-Sotalol With No Antiarrhythmic Drug Treatment,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):46-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/9935007/pubmed\" target=\"_blank\" id=\"9935007\">9935007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lennest&aring;l R, Otterblad Olausson P, and K&auml;ll&eacute;n B. Maternal Use of Antihypertensive Drugs in Early Pregnancy and Delivery Outcome, Notably the Presence of Congenital Heart Defects in the Infants. <i>Eur J Clin Pharmacol</i>. 2009;65(6):615-625.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/19198819/pubmed\" target=\"_blank\" id=\"19198819\">19198819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mason JW, &ldquo;A Comparison of Seven Antiarrhythmic Drugs in Patients With Ventricular Tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators,&rdquo; <i>N Engl J Med</i>, 1993, 329(7):452-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/8332150/pubmed\" target=\"_blank\" id=\"8332150\">8332150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namouz-Haddad S, Koren G. Fetal pharmacotherapy 2: fetal arrhythmia. <i>J Obstet Gynaecol Can</i>. 2013;35(11):1023-1027.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/24246403 /pubmed\" target=\"_blank\" id=\"24246403 \">24246403 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 suppl 3):s729-s767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Hare MF, Leahey W, Murnaghan GA, et al. Pharmacokinetics of Sotalol During Pregnancy. <i>Eur J Clin Pharmacol</i>. 1983;24(4):521-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/6861867/pubmed\" target=\"_blank\" id=\"6861867\">6861867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Hare MF, Murnaghan GA, Russell CJ. Sotalol as a Hypotensive Agent in Pregnancy. <i>Br J Obstet Gynaecol</i>. 1980;87(9):814-820.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/7426541/pubmed\" target=\"_blank\" id=\"7426541\">7426541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacifico A, Hohnloser SH, Williams JH, et al, &ldquo;Prevention of Implantable-Defibrillator Shocks by Treatment With Sotalol. d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group,&rdquo; <i>N Engl J Med</i>, 1999, 340(24):1855-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/10369848/pubmed\" target=\"_blank\" id=\"10369848\">10369848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saul JP, Ross B, Schaffer MS, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Sotalol in a Pediatric Population With Supraventricular and Ventricular Tachyarrhythmia,&rdquo; <i>Clin Pharmacol Ther</i>, 2001a, 69(3):145-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/11240979/pubmed\" target=\"_blank\" id=\"11240979\">11240979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saul JP, Schaffer MS, Karpawich PP, et al, &ldquo;Single-Dose Pharmacokinetics of Sotalol in a Pediatric Population With Supraventricular and/or Ventricular Tachyarrhythmia,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41(1):35-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. <i>Am J Ther</i>. 2010;17(4):365-372.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/20562595/pubmed\" target=\"_blank\" id=\"20562595\">20562595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sonesson SE, Fouron JC, Wesslen-Eriksson E, et al. Foetal Supraventricular Tachycardia Treated With Sotalol. <i>Acta Paediatr</i>. 1998;87(5):584-587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/9641744/pubmed\" target=\"_blank\" id=\"9641744\">9641744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorine (sotalol) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sotalol Hydrochloride Injection [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sotylize (sotalol) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang S, Lo CY, Lo WK, et al. Sotalol-induced Torsade de pointes in a CAPD patient--successful treatment with intermittent peritoneal dialysis. <i>Perit Dial Int</i>. 1997;17(2):207-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/9159848/pubmed\" target=\"_blank\" id=\"9159848\">9159848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waldo AL, Camm AJ, deRuyter H, et al, &ldquo;Effect of d-sotalol on Mortality in Patients With Left Ventricular Dysfunction After Recent and Remote Myocardial Infarction. The SWORD Investigators. Survival With Oral d-Sotalol,&rdquo; <i>Lancet</i>, 1996, 348(9019):7-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/8691967/pubmed\" target=\"_blank\" id=\"8691967\">8691967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winters SL, Kukin M, Pe E, et al. Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. <i>Am J Cardiol</i>. 1993;72:38A-43A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/8346725/pubmed\" target=\"_blank\" id=\"8346725\">8346725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong DG, Spence JD, Lamki L, et al, &ldquo;Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,&rdquo; <i>Lancet</i>, 1986, 1(8488):997-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/2871333 /pubmed\" target=\"_blank\" id=\"2871333 \">2871333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Dental Nonsteroidal Anti-inflammatory Drugs and Prostaglandin-Based Drug Interactions, Part Two,&rdquo; <i>Gen Dent</i>, 1992, 40(2):104, 106, 108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/1354194 /pubmed\" target=\"_blank\" id=\"1354194 \">1354194 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo; <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/7911769 /pubmed\" target=\"_blank\" id=\"7911769 \">7911769 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo; <i>J Am Coll Cardiol</i>, 2006, 48(5):247-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-drug-information/abstract-text/16949478 /pubmed\" target=\"_blank\" id=\"16949478 \">16949478 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9941 Version 206.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709415\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222498\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222499\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F222538\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F222502\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F222521\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F222503\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F222504\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22560158\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9830566\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222468\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F222453\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F222472\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F222471\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744909\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222546\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222460\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222476\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222457\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300075\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222462\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F222494\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222464\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F222480\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F222481\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F222466\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222456\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F222475\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222479\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038831\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9941|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/78350\" class=\"graphic graphic_figure\">- Age nomogram</a></li></ul></li><li><div id=\"DRUG_GEN/9941|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sotalol-patient-drug-information\" class=\"drug drug_patient\">Sotalol: Patient drug information</a></li><li><a href=\"topic.htm?path=sotalol-pediatric-drug-information\" class=\"drug drug_pediatric\">Sotalol: Pediatric drug information</a></li></ul></div></div>","javascript":null}